Janssen Business Development

Identifying Pathways to Better Health
Through Collaboration

Learn more

About Us

Johnson & Johnson Innovation | Janssen Business Development seeks to identify collaborative opportunities that will create transformative value for our partners and the world.

Driving Collaborative Innovation to Accelerate Breakthroughs

If you are with an established pharmaceutical company, mid-sized to large biotechnology company, seek a collaboration or merger & acquisition discussions, or have a compound that has shown proof of concept in humans, make the connection with Johnson & Johnson Innovation, Janssen Business Development.

Janssen Business Development is very active in acquiring assets, companies, and technologies as well as entering into strategic collaborations, including joint ventures, developments, and commercial partnerships.


  • Patrick Verheyen
    Global Head, Janssen Business Development
  • Nicholas Franco
    Actelion Executive Vice President, Chief Business Development Officer
  • Johan L. J. Verbeeck
    VP Business Development, Immunology
  • Denise McGinn
    VP, Business Development, Cardiovascular Metabolism [and Japan]
  • Lucinda Warren
    VP, Business Development, Neuroscience
  • Debi Watson
    VP, Business Development, Oncology


The Janssen Business Development team focuses on mid- and late-stage collaborations with established pharmaceutical and larger biotechnology companies to accelerate breakthrough innovation to solve unmet medical needs and create real value in Janssen’s six defined therapeutic areas.

Strong Science Is at the Heart of Everything We Do

Our approach meaningfully integrates deal makers with science leaders from the very beginning. Having a clear and focused strategy that is grounded in the science allows the Janssen Business Development team to shape better deals and achieve in-market impact faster by understanding where each partner can add value.

Proven Two-Way Value Can Be Found in Every Partnership

The Janssen Business Development team has a proven, positive track record of deal performance. Our thoughtful approach to risk-taking includes spending the time to understand the needs of our partners so that deals can be structured to maximize value for all parties.

Dynamic Approaches Pave the Way to Success

Since no two deals are exactly alike, the Janssen Business Development team employs a flexible and adaptive approach to tailor the optimal deal structure to each unique partner opportunity. Our direct access to decision makers within Johnson & Johnson allows for creative and timely problem solving to optimize success.

True Collaboration Drives All of Our Actions

We are focused on genuine collaborations and seek out relationships with partners who desire transparency and openness, which we believe leads to new ideas and better solutions. Our goal is to form active partnerships where we can bring the full strength of Johnson & Johnson to bear to create a lasting and valuable relationship.

Focus Areas

Our Pharmaceuticals business is divided into six core areas, Cardiovascular & Metabolism; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Janssen Business Development seeks innovation across all of these areas where there is significant unmet patient need. 

  • Type 2 Diabetes
    Cardiovascular and Metabolism
    Cardiovascular and Metabolism
  • Psoriasis, Inflammatory Bowel Disease, Rheumatoid Arthritis
  • Respiratory Infections, Hepatitis
    Diseases and Vaccines
    Infectious Diseases and Vaccines
  • Mood Disorders, Alzheimer's Disease
  • Prostate Cancer, Lung Cancer, Hematologic Malignancies
  • Pulmonary arterial hypertension, Idiopathic pulmonary fibrosis, Chronic thromboembolic pulmonary hypertension
    Pulmonary Hypertension
    Pulmonary Hypertension


  • Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. Announce Agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. to ...

    New Brunswick, N.J.
    January 7, 2016

    Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. today announced an exclusive license agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a Chinese domestic pharmaceutical company and subsidiary of Sino Biopharma, Ltd. focused on liver diseases, to develop, manufacture and commercialize, outside of China, undisclosed immune-modulating agents to treat human diseases, including curative treatment of chronic Hepatitis B virus (HBV) infection.

  • Johnson & Johnson Announces Completion of Novira Therapeutics, Inc. Acquisition

    New Brunswick, NJ
    December 4, 2015

    Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing innovative therapies for curative treatment of chronic hepatitis B virus (HBV) infection. The transaction was originally announced on November 4, 2015. Financial terms of the transaction have not been disclosed.


  • Collaborating to Study New Treatment for Insomnia Related to Depression

    February 3, 2015

    One of the promising scientific collaborations in our neuroscience pipeline is with Minerva Neurosciences, focusing on MIN-202 – a selective orexin-2 antagonist being studied for the treatment of insomnia and potentially other disorders associated with sleep disorders such as major depressive disorder, an area of strategic focus for Janssen.

Contact us

Make the Connection

We look forward to our first discussion. If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.

Johan Verbeeck, DVM, MsC
Johnson & Johnson Innovation,
Janssen Business Development
Email: jverbee2@ITS.JNJ.com
Telephone: +1 609-730-4532



Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.